Cette page est disponible uniquement en anglais

We advised

  • Acerta Pharma on its acquisition by AstraZeneca for up to USD 7 billion
  • Arvelle Therapeutics in its USD 180 million (€159.1m) Series A
  • ASIT biotech with its business combination with DMS Imaging and capital increase.
  • Avania Group with the sale of a majority stake in Avania to Astorg
  • Cerba Healthcare on its acquisition of Viroclinics
  • Batavia Biosciences on its auction sale to CJ Corp
  • Dezima Pharma on its up to 1.5 billion acquisition by Amgen
  • Eagle Pharmaceuticals on the acquisition of Acacia Pharma Group plc.
  • Fysicon on its acquisition by Canon Medical Systems Cooperation
  • Getinge on its acquisition of Applikon Biotechnology
  • Gingko Bioworks on its acquisition of Dutch DNA
  • InflaRx in its listing on NASDAQ
  • Keensight Capital on the acquisition of Symeres
  • Lava Therapeutics on listing on NASDAQ
  • Lumick’s Technologies on its Series D round
  • Mediq with the acquisition of Remedus.
  • Mylan in its USD 22 billion merger with Pfizer’s spin-out Upjohn, its EUR 30 billion unsolicited voluntary public offer for Perrigo Company plc, as well as assisting Mylan in its pending USD 7.5 million bid for Meda
  • Neogene Therapeutics on its sale to AstraZeneca
  • NewAmsterdam Pharma on its business combination with Frazier Healthcare
  • Pharming Group with its public company work
  • Rhythm Pharmaceutical on its acquisition of Xinvento
  • S-Biomedic on the sale of a majority stake to Beiersdorf.
  • Sanofi on its acquisitions of Kiadis Pharma and Ablynx
  • Siemens Healthineers on its strategic collaboration with Screenpoint Medical
  • Suazio on the sale of their shares to NAMSA.
  • Synaffix on its sale to Lonza Group Ag
  • Staten Biotechnology on the collaboration with Novo Nordisk
  • VarMx on its seed- and series A and B investments
  • VIB, since end 2012, NautaDutilh is the preferred legal partner of VIB
  • Vico Therapeutics Holding BV with its EUR 27 million Series A financing round.
  • Wacker on its acquisition of Synco BioPartners

Notification de cookies

Cette fonctionnalité utilise des cookies tiers. Modifiez votre cookie préférences pour visualiser ce contenu ou afficher plus d'informations.
Ces cookies assurent le bon fonctionnement du site. Ces cookies ne peuvent pas être désactivés.
Ces cookies peuvent être placés par des tiers, tels que YouTube ou Vimeo.
En désactivant certaines catégories, les fonctionnalités associées au sein du site risquent de ne plus fonctionner correctement. Vous pouvez modifier vos préférences ultérieurement. Voir plus d'informations.